甘李药业跌2.01%，成交额6.90亿元，主力资金净流出3870.82万元

Core Viewpoint - 甘李药业's stock has experienced fluctuations, with a notable increase of 71.97% year-to-date, but a recent decline of 6.90% over the past five trading days [1] Financial Performance - For the first half of 2025, 甘李药业 reported revenue of 2.067 billion yuan, a year-on-year increase of 57.18%, and a net profit attributable to shareholders of 604 million yuan, reflecting a growth of 101.96% [2] - Cumulative cash dividends since the company's A-share listing amount to 1.612 billion yuan, with 1.018 billion yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for 甘李药业 increased to 77,300, up by 3.08%, while the average number of circulating shares per person decreased by 2.99% to 7,165 shares [2] - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 7.5099 million shares, an increase of 174,800 shares from the previous period [3]